Literature DB >> 24745679

Eosinophilia in mast cell disease.

Anna Kovalszki1, Peter F Weller2.   

Abstract

Eosinophils and mast cells coexist in clonal and nonclonal disorders. The interplay between these cells is complex and not fully understood. Discussed are both allergic/nonclonal disorders in which both cell types are increased in number are likely to play a role in pathogenesis and clonal disorders in which both cell types are affected and play key roles in pathogenesis. Finally, some treatment options, keeping both disorders in mind, are discussed. Future directions in thinking about these disorders are also briefly explored.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chronic eosinophilic leukemia (CEL); Eosinophilia; FIP1L1-PDGFRA fusion; Hypereosinophilic syndrome; Imatinib; Systemic mastocytosis; Tryptase

Mesh:

Substances:

Year:  2014        PMID: 24745679      PMCID: PMC4083463          DOI: 10.1016/j.iac.2014.01.013

Source DB:  PubMed          Journal:  Immunol Allergy Clin North Am        ISSN: 0889-8561            Impact factor:   3.479


  33 in total

1.  Involvement of mast cells in eosinophilic esophagitis.

Authors:  J Pablo Abonia; Carine Blanchard; Bridget Buckmeier Butz; Heather F Rainey; Margaret H Collins; Keith Stringer; Philip E Putnam; Marc E Rothenberg
Journal:  J Allergy Clin Immunol       Date:  2010-06-09       Impact factor: 10.793

2.  How I treat patients with advanced systemic mastocytosis.

Authors:  Peter Valent; Wolfgang R Sperr; Cem Akin
Journal:  Blood       Date:  2010-09-20       Impact factor: 22.113

3.  Activated mucosal mast cells differentiate eosinophilic (allergic) esophagitis from gastroesophageal reflux disease.

Authors:  Richard Kirsch; Rana Bokhary; Margaret A Marcon; Ernest Cutz
Journal:  J Pediatr Gastroenterol Nutr       Date:  2007-01       Impact factor: 2.839

4.  Physical interactions between mast cells and eosinophils: a novel mechanism enhancing eosinophil survival in vitro.

Authors:  M Elishmereni; H T Alenius; P Bradding; S Mizrahi; A Shikotra; Y Minai-Fleminger; D Mankuta; R Eliashar; G Zabucchi; F Levi-Schaffer
Journal:  Allergy       Date:  2010-10-26       Impact factor: 13.146

5.  Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis.

Authors:  Melody C Carter; Jamie A Robyn; Peter B Bressler; John C Walker; Gail G Shapiro; Dean D Metcalfe
Journal:  J Allergy Clin Immunol       Date:  2007-05-03       Impact factor: 10.793

6.  Improved detection of the KIT D816V mutation in patients with systemic mastocytosis using a quantitative and highly sensitive real-time qPCR assay.

Authors:  Thomas Kristensen; Hanne Vestergaard; Michael Boe Møller
Journal:  J Mol Diagn       Date:  2011-03       Impact factor: 5.568

7.  Treatment of patients with the hypereosinophilic syndrome with mepolizumab.

Authors:  Marc E Rothenberg; Amy D Klion; Florence E Roufosse; Jean Emmanuel Kahn; Peter F Weller; Hans-Uwe Simon; Lawrence B Schwartz; Lanny J Rosenwasser; Johannes Ring; Elaine F Griffin; Ann E Haig; Paul I H Frewer; Jacqueline M Parkin; Gerald J Gleich
Journal:  N Engl J Med       Date:  2008-03-16       Impact factor: 91.245

8.  Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies.

Authors:  Animesh Pardanani; Ken-Hong Lim; Terra L Lasho; Christy Finke; Rebecca F McClure; Chin-Yang Li; Ayalew Tefferi
Journal:  Blood       Date:  2009-08-27       Impact factor: 22.113

9.  KIT D816V-associated systemic mastocytosis with eosinophilia and FIP1L1/PDGFRA-associated chronic eosinophilic leukemia are distinct entities.

Authors:  Irina Maric; Jamie Robyn; Dean D Metcalfe; Michael P Fay; Melody Carter; Todd Wilson; Weiming Fu; Jennifer Stoddard; Linda Scott; Marilyn Hartsell; Arnold Kirshenbaum; Cem Akin; Thomas B Nutman; Pierre Noel; Amy D Klion
Journal:  J Allergy Clin Immunol       Date:  2007-07-12       Impact factor: 10.793

10.  Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy.

Authors:  Princess U Ogbogu; Bruce S Bochner; Joseph H Butterfield; Gerald J Gleich; Johannes Huss-Marp; Jean Emmanuel Kahn; Kristin M Leiferman; Thomas B Nutman; Florian Pfab; Johannes Ring; Marc E Rothenberg; Florence Roufosse; Marie-Helene Sajous; Javed Sheikh; Dagmar Simon; Hans-Uwe Simon; Miguel L Stein; Andrew Wardlaw; Peter F Weller; Amy D Klion
Journal:  J Allergy Clin Immunol       Date:  2009-12       Impact factor: 10.793

View more
  5 in total

1.  Prognostic impact of eosinophils in mastocytosis: analysis of 2350 patients collected in the ECNM Registry.

Authors:  Hanneke C Kluin-Nelemans; Andreas Reiter; Anja Illerhaus; Bjorn van Anrooij; Karin Hartmann; Lambertus F R Span; Aleksandra Gorska; Marek Niedoszytko; Magdalena Lange; Luigi Scaffidi; Roberta Zanotti; Patrizia Bonadonna; Cecelia Perkins; Chiara Elena; Luca Malcovati; Khalid Shoumariyeh; Nikolas von Bubnoff; Roberta Parente; Massimo Triggiani; Juliana Schwaab; Mohamad Jawhar; Francesca Caroppo; Anna Belloni Fortina; Knut Brockow; Alexander Zink; David Fuchs; Alex Kilbertus; Akif Selim Yavuz; Michael Doubek; Mattias Mattsson; Hans Hagglund; Jens Panse; Vito Sabato; Elisabeth Aberer; Dietger Niederwieser; Christine Breynaert; Judit Várkonyi; Vanessa Kennedy; Olivier Lortholary; Thilo Jakob; Olivier Hermine; Julien Rossignol; Michel Arock; Jason Gotlib; Peter Valent; Wolfgang R Sperr
Journal:  Leukemia       Date:  2019-11-18       Impact factor: 11.528

Review 2.  Eosinophilia.

Authors:  Anna Kovalszki; Peter F Weller
Journal:  Prim Care       Date:  2016-10-14       Impact factor: 2.907

3.  Characterization of skin surface and dermal microbiota in dogs with mast cell tumor.

Authors:  Valentina Zamarian; Carlotta Catozzi; Anna Cuscó; Damiano Stefanello; Roberta Ferrari; Fabrizio Ceciliani; Olga Francino; Armand Sánchez; Valeria Grieco; Davide Zani; Andrea Talenti; Paola Crepaldi; Cristina Lecchi
Journal:  Sci Rep       Date:  2020-07-28       Impact factor: 4.379

Review 4.  Mastocytosis: from a Molecular Point of View.

Authors:  Daniel Elieh Ali Komi; Todd Rambasek; Stefan Wöhrl
Journal:  Clin Rev Allergy Immunol       Date:  2018-06       Impact factor: 8.667

5.  [Spectrum of gene mutations and clinical features in adult acute myeloid leukemia with normal karyotype].

Authors:  L J Sun; J X Huang; Q Q Wang; F Hou; H Xu; H G Zhao; W Wang; H R Fei; X Shi
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2021-05-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.